Reports Outline Carcinomas Study Findings from Memorial Sloan-Kettering Cancer Center (Characterization and Management of Adverse Reactions From the Clear Study In Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab).

Předmět:	PEMBROLIZUMAB RENAL cell carcinoma CARCINOMA PROTEIN-tyrosine kinase inhibitors SORAFENIB
Zdroj:	Immunotherapy Weekly; 4/11/2023, p570-570, 1p
Abstrakt:	Strategies for effectively managing ARs included baseline monitoring, drug-dose modifications, and/or concomitant medications. Keywords: New York City; State:New York; United States; North and Central America; Cancer; Carcinomas; Drugs and Therapies; Health and Medicine; Immunologic Agents; Immunotherapy; Kidney; Kinase Inhibitors; Lenvatinib Therapy; Monoclonal Antibodies; Nephrology; Oncology; Pembrolizumab Therapy; Pharmaceuticals; Receptor Tyrosine Kinase Inhibitors EN New York City State:New York United States North and Central America Cancer Carcinomas Drugs and Therapies Health and Medicine Immunologic Agents Immunotherapy Kidney Kinase Inhibitors Lenvatinib Therapy Monoclonal Antibodies Nephrology Oncology Pembrolizumab Therapy Pharmaceuticals Receptor Tyrosine Kinase Inhibitors 570 570 1 04/10/23 20230411 NES 230411 2023 APR 10 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators discuss new findings in Oncology - Carcinomas. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu